Madrigal Pharmaceuticals, Inc. Stock News

CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 15, 2025 to 4 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Induc...

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST.

Summit Therapeutics has an incredibly promising cancer candidate in the pipeline. Madrigal Pharmaceuticals made a breakthrough that could drive strong results for years to come.

CONSHOHOCKEN, Pa., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 1, 2025 to 24 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Induc...

CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 15, 2025 to three new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 I...

Madrigal Pharmaceuticals, Inc. ( MDGL ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:30 AM EST Company Participants William Sibold - CEO, President & Director Mardi Dier - Executive VP & CFO David Soergel - Executive VP & Chief Medical Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Divisio...

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:

Rezdiffra ® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality of life measures in patients with and without cirrhosis, with sustained effect through two years of treatment New analysis examining effects of Rezdiffra trea...